Making Connections

MSIF News


	Summaries of new MSIF activities, events, projects, programmes, resources, publications and more.

Take part in our online survey

The next edition of MS in focus looks at caregiving and MS. To help inform this edition of the magazine, please take part in our online survey.

Flyer about MSIF

We have recently produced a flyer about MSIF and our work. We would be pleased to send copies to any MS societies, support groups, MS clinics or individuals interested in displaying them or distributing them at events.

People with MS News


	Summaries of news, views and achievements from people with MS around the world. Do you, or does someone you know with MS, have news, views or achievements to share? If so, please contact Lucy Hurst, MSIF's Information and Communications Manager.

Profile of the Month : January 2008

Satu Salonen

Country: Finland
Age: 55
Year of diagnosis: 1999
Occupation: Former company director, then pensioner and now author

English Spanish Italian French Russian German

Research News


	Summaries of all the latest research findings on MS selected by a team based at the Institute of Neurology, London.

ECTRIMS

Due to the 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) there is no Research news this week.

MS News


	Summaries of MS news from websites around the world.

Belgium MS Society moves

source: Belgium MS Society

On September 25, the Belgium MS Society moved to new, larger premises.

Clinical trial results for oral therapy fingolimod show reduction of disease activity: Larger study now recruiting participants

source: MS Society of Canada

Results of a Phase II controlled clinical trial of oral fingolimod (also known as FTY720) have been published in The New England Journal of Medicine. The study found fingolimod significantly reduced MS attack rates and signs of inflammation on MRI scans.

Promising early results for Campath in relapsing remitting MS

source: UK MS Society

The UK MS Society has welcomed the interim results of a phase II trial of Campath (alemtuzumab).

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

Click here to learn more about the work of the Making Connections sponsor.